{"nctId":"NCT00108082","briefTitle":"The CLEVER Study - Coreg And Left Ventricular Mass Regression","startDateStruct":{"date":"2005-01"},"conditions":["Hypertrophy, Left Ventricular"],"count":287,"armGroups":[{"label":"Carvedilol CR","type":"EXPERIMENTAL","interventionNames":["Drug: carvedilol MR","Drug: lisinopril"]},{"label":"Atenolol","type":"EXPERIMENTAL","interventionNames":["Drug: atenolol","Drug: lisinopril"]},{"label":"Lisinopril","type":"EXPERIMENTAL","interventionNames":["Drug: lisinopril"]}],"interventions":[{"name":"carvedilol MR","otherNames":["Carvedilol controlled release or modified release"]},{"name":"atenolol","otherNames":[]},{"name":"lisinopril","otherNames":["carvedilol MR","atenolol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Stage 1 or Stage 2 hypertension.\n* Left ventricular hypertrophy.\n\nExclusion criteria:\n\n* In atrial fibrillation.\n* Takes beta-blocker for MI (myocardial infarction) or arrhythmia.\n* Has uncontrolled diabetes, uncontrollable or symptomatic arrhythmias, unstable angina, second or third degree heart block, history of MI, COPD (chronic obstructive pulmonary disease), liver or kidney disease.\n* Uses beta-2-agonists.\n* Unable to undergo MRI (magnetic resonance imaging).\n* Females of childbearing potential.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12","description":"LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m\\^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.34","spread":"0.850"},{"groupId":"OG001","value":"-6.67","spread":"0.756"},{"groupId":"OG002","value":"-7.94","spread":"0.850"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12","description":"LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.19","spread":"0.407"},{"groupId":"OG001","value":"-3.37","spread":"0.361"},{"groupId":"OG002","value":"-3.98","spread":"0.407"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12","description":"LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.74","spread":"1.732"},{"groupId":"OG001","value":"-14.17","spread":"1.540"},{"groupId":"OG002","value":"-17.17","spread":"1.734"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12","description":"LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.35","spread":"4.027"},{"groupId":"OG001","value":"-20.06","spread":"3.672"},{"groupId":"OG002","value":"-18.48","spread":"3.998"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12","description":"LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.78","spread":"2.292"},{"groupId":"OG001","value":"-12.51","spread":"2.100"},{"groupId":"OG002","value":"-11.61","spread":"2.280"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12","description":"LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.76","spread":"8.338"},{"groupId":"OG001","value":"-40.56","spread":"7.645"},{"groupId":"OG002","value":"-38.58","spread":"8.296"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12","description":"LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.364","spread":"2.2853"},{"groupId":"OG001","value":"6.763","spread":"2.3870"},{"groupId":"OG002","value":"-3.406","spread":"2.8779"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.513","spread":"1.3624"},{"groupId":"OG001","value":"-0.565","spread":"1.5154"},{"groupId":"OG002","value":"1.088","spread":"1.5630"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12","description":"LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"1.578"},{"groupId":"OG001","value":"-4.29","spread":"1.397"},{"groupId":"OG002","value":"-3.04","spread":"1.581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"2.848"},{"groupId":"OG001","value":"-2.45","spread":"2.522"},{"groupId":"OG002","value":"-7.45","spread":"2.858"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.685"},{"groupId":"OG001","value":"2.16","spread":"0.607"},{"groupId":"OG002","value":"-0.01","spread":"0.685"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12","description":"LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.38","spread":"2.067"},{"groupId":"OG001","value":"-4.74","spread":"1.892"},{"groupId":"OG002","value":"-5.34","spread":"2.086"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.07","spread":"3.389"},{"groupId":"OG001","value":"-3.64","spread":"3.108"},{"groupId":"OG002","value":"-9.37","spread":"3.420"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"0.751"},{"groupId":"OG001","value":"2.33","spread":"0.687"},{"groupId":"OG002","value":"0.63","spread":"0.756"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12","description":"Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.32","spread":"1.755"},{"groupId":"OG001","value":"-21.12","spread":"1.535"},{"groupId":"OG002","value":"-22.53","spread":"1.708"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.77","spread":"1.103"},{"groupId":"OG001","value":"-14.05","spread":"0.976"},{"groupId":"OG002","value":"-11.13","spread":"1.117"}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12","description":"BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) \\[Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"48.3","spread":null},{"groupId":"OG002","value":"-39.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12","description":"CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). \\[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.63","spread":null},{"groupId":"OG001","value":"-3.22","spread":null},{"groupId":"OG002","value":"2.70","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12","description":"Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). \\[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"-1.3","spread":null},{"groupId":"OG002","value":"-1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"-4.0","spread":null},{"groupId":"OG002","value":"-2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":null},{"groupId":"OG001","value":"-4.7","spread":null},{"groupId":"OG002","value":"-1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"7.1","spread":null},{"groupId":"OG002","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12","description":"Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. \\[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.1","spread":null},{"groupId":"OG001","value":"-20.1","spread":null},{"groupId":"OG002","value":"-21.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4},"commonTop":["Headache","Cough","Dizziness","Fatigue","Nasopharyngitis"]}}}